Galenica Ag · SIX:GALE
Galenica — Investor Presentation (March 2025)
86 slides from Galenica's investor presentation, Mar 10, 2025
Slide 1: Investor Presentation Galenica Group March 2025
Investor Presentation Galenica Group March 2025
Slide 2: Table of contents
Table of contents About Galenica page 03 Market environment page 29 Business performance page 40 Governance page 58 Sustainability page 69 Outlook page 78 March 2025 Investor Presentation Galenica Group 2
Slide 3: About Galenica
About Galenica
Slide 4: Galenica in figures
Galenica in figures Net sales1 EBIT adjusted1,2 Galenica Group Galenica Group Leading healthcare provider in Switzerland 376 own pharmacies 27% 34% CHF CHF Employees 3,921.1 211.0 (Headcount) million million > 7,900 66% 73% Dividend yield1 3.1% Products & Care Logistics & IT Products & Care Logistic
Slide 5: Building the leading Swiss healthcare platform
Building the leading Swiss healthcare platform IPO Joint Venture Creation of Amavita uniform Opening of highly brand in Switzerland automated distribution centre in Niederbipp Acquisition Acquisition Umsatz +10.2% 2000 2002 2005 2007 2008 2009 2013 EBIT 2017 +26.4% Organic and acquisition-led expans
Slide 6: Building the leading Swiss healthcare platform
Building the leading Swiss healthcare platform Acquisition Strategic partnership Acquisition Acquisition Acquisition Acquisition Acquisition Participation 2018 2019 2020 2021 2022 2023 2024 Relaunch Joint Venture Joint Venture Acquisition Acquisition Participation Strategic partnership Strategic par
Slide 7: Switzerland's leading fully integrated healthcare provider
Switzerland‘s leading fully integrated healthcare provider Largest network of Wide range of pharmacies in services for patients Switzerland with over and professional 500 pharmacies, service providers online and offline Well-known brands Leading provider of and products and logistics and IT in the e
Slide 8: Values, vision and strategy
Values Added value in the network Shaping the future We generate value for customers We are shaping the healthcare and partners of tomorrow Vision Omni-Channel Digital Health Health Services & Products Connecting Healthcare Strategy Strategy Sustainably successful Pioneers in transition We work effi
Slide 9: Strong on the market
Galenica @ Strong on the market .® é ° Me ° eo. PADMA
Slide 10: Our business areas
Our business areas Products & Care1 Logistics & IT1 Net sales EBIT2 Net sales EBIT2 1,700m CHF 157m CHF 3,241m CHF 57m CHF Retail B2C Professionals B2B Local Pharmacies Pharmacies at Products & Services for Wholesale Logistics & IT Home Brands Professionals Services Net sales Net sales Net sales Net
Slide 11: Local pharmacies: Three largest pharmacy chains in Switzerland
Local pharmacies Three largest pharmacy chains in Switzerland Key takeaways Largest branded pharmacy network by number of − Largest pharmacy network offers broad product range, pharmacies in Switzerland1 including well-known own brands, as well as health services and tests 204 − Built organically an
Slide 12: Local pharmacies: Broad range of product and service offerings
Local pharmacies Broad range of product and service offerings Amavita and Sun Store product offering Service offerings in local pharmacies (selection) in % of sales1 Primary Care Health Checks Prescription medicines of which originals 7% of which generics 20% 37% of which service fees COVID-19 Tests
Slide 13: Local pharmacies: Always available where our customers are
Local pharmacies Always available where our customers are Widely spread pharmacy network covers every Demonstrated M&A track record with an average of 8 Region in Switzerland pharmacies acquired and 3 net pharmacies added per year over the last 5 years 13 2020 2021 2022 2023 2024 24 Pharmacies acqui
Slide 14: Pharmacies at home: Mail order pharmacies and home care services
Pharmacies at home: Mail order pharmacies and home care services Key takeaways Total Retail Net Sales2 − Business area covers both home care (Bichsel) and Mail-order pharmacies 5% (webshops / Cannaplant) with a share of 5% of Total Retail sales (B2C) CHF − Both Homecare and Mail-order 1,442 pharmaci
Slide 15: Bichsel home care services
Pharmacies at home Bichsel home care services for over 13,000 active patients across Switzerland Key takeaways − Improve quality of life, e.g. enhanced mobility, continuation in familiar setting − Efficient provision of services compared with in-patient alternatives − Patients from toddlers to the e
Slide 16: Mediservice: Joint Venture with Redcare Pharmacy
Pharmacies at home Mediservice: Joint Venture with Redcare Pharmacy N.V. Market Share Mail-order pharmacies1 Market leading online and mail-order1 70% pharmacy in Switzerland The business activities of Mediservice and shop-apotheke.ch are combined in the joint venture: 60% − Mediservice customers co
Slide 17: Strong brands for the Swiss Consumer Healthcare Market
Products & Brands Strong brands for the Swiss Consumer Healthcare Market Key takeaways Selected own brands − Leading position1 in the Swiss consumer healthcare market (CHC) − Preferred Consumer Health partner for Swiss Pharmacies & Drugstores − Broad Sales & Training force − Expanding portfolio of o
Slide 18: Verfora market share in Swiss CHC market
Products & Brands Strong brands for the Swiss Consumer Healthcare Market Verfora market share Market share of main OTC product in Swiss CHC market1 categories of Verfora1 in 2024 OTC products 13.9% market share Vitamins, minerals & CHF 253.3 million nutritional supplements Pain relief Personal care
Slide 19: Proven M&A track record as key driver for market share growth
Products & Brands: Proven M&A track record as key driver for market share growth Verfora growth strategy − Big OTC brands − Emerging platforms complementary medicine, beauty & Rx − New distribution agreements − Acquisitions of brands / companies − International expansion via distributors March 2025
Slide 20: Proven M&A track record as key driver for market share growth
Products & Brands Proven M&A track record as key driver for market share growth Distribution Acquisition Boiron® OTC Hedoga Beauty Group Complementary Medicine Distribution 10.0% Distribution Allergosan® Vicks and Acquisition Metamucil Distribution Dr. Wild ThermaCare® Acquisition Merfen® and Acquis
Slide 21: Services for Professionals
Services for Professionals We support healthcare professionals with high quality services • Lifestage Solutions develops and operates a fully integrated digital trading platform for home care organisations and nursing homes • Strong customer focus: the platform simplifies daily workflows for its cus
Slide 22: One digital platform for home care services
Services for Professionals One digital platform for home care services Artificial nutrition and parenteral therapies Overview of services Care materials (MiGeL) and billing Galenica’s Home doctors comprehensive range of services relieves the burden on specialists and optimises work processes Regiona
Slide 23: Wholesale: Leader in wholesale distribution
Wholesale Leader in wholesale distribution Key takeaways Wholesale market share1 Wholesale market share1 % physician channel % pharmacy channel − Wide product range with around 100,000 products in pharma, non-pharma, practice & laboratory equipment and medical devices, whereof around 50% in stock 30
Slide 24: Wholesale distribution with four distribution centers
Wholesale Leader in wholesale distribution Wholesale distribution with four distribution centers Customers by channel Pharmacies ~ 1,300 Drugstore ~ 300 Medical practices > 5,600 Hospitals/Nursing homes > 570 March 2025 Investor Presentation Galenica Group 24
Slide 25: Logistics & IT Services: Leader in pre-wholesale distribution
Logistics & IT Services Leader in pre-wholesale distribution Key takeaways Pre-wholesale market share1) Warehouse capacity − Third-party logistics provider No. 3 9% 35,200 m2 for the pharmaceutical industry (pre-wholesaling) including No. 2 38% additional services (labeling, repacking, clinical tria
Slide 26: Strong IT & Digital Business competencies
Logistics & IT Services: Strong IT&Digital Business competencies to drive digital transformation Key takeaways Internal IT Services Market offering − Digital product master data and scientific databases (Index) Projects & Consulting Index − Modular eHealth Platform for efficiency and patient safety
Slide 27: Approach towards more patient safety, convenience and efficiency
Logistics & IT Services Our approach towards more patient safety, convenience and efficiency Clinical Decision Support (CDS.CE) (medication and vaccination) Diagnosis Medication Master Data Anamnesis Prescription Patients on-/offline E-Prescription e-Mediplan Therapy March 2025 Investor Presentation
Slide 28: Galenica as preferred partner in Swiss Healthcare
Strategic partnerships Galenica as preferred partner in Swiss Healthcare strategic partnerships Product Health Digital eHealth Pharmacies Logistics distribution Insurances Platforms Solutions - Basic insurance models - Verfora is preferred distribution partner for products in - JV with Planzer - JV
Slide 29: Market environment
Market environment
Slide 30: Swiss healthcare market: resilient and stable growth
Swiss healthcare market Proven track record of resilient and stable growth Development of Swiss healthcare retail sector1 in billion CHF (based on ex-manufacturer price) 2024-27 CAGR 4%2 7 2013-24 CAGR 3.8% 6 6.3 6.6 5.8 6.1 5 5.6 5.3 4.9 4 4.4 4.4 4.5 4.6 4.1 4.2 3 3.9 3.9 2 1 0 2013 2014 2015 2016
Slide 31: Swiss pharmaceutical market FY 2024
Swiss pharmaceutical market FY 2024 Total market growth CHF 7,688.0 million (+3.5%) Hospitals 200.0 million packs (+0.5%) CHF 1,859.7 million (+2.4%) 15.5 million packs (-1.9%) 24.2% Drugstores 43.3% Local Pharmacies CHF 62.9 million (-1.6%) 0.8% CHF 3,332.7 million (+3.5%) 6.0 million packs (-3.7%)
Slide 32: Swiss pharmaceutical market
Swiss pharmaceutical market Strong growth in H2 supported by two additional sales days in million CHF 710 690 670 650 630 610 590 570 550 530 510 490 470 450 Jan Feb Mrz Apr Mai Jun Jul Aug Sep Okt Nov Dez 2022 2023 2024 Source: IQVIA APO/SD/DRO/SPI Index, Swissmedic A, B, D Medicines Swissmedic lis
Slide 33: Galenica as key driver of generic substitution in Switzerland
Swiss pharmaceutical market Galenica as key driver of generic substitution in Switzerland Drugs reimbursable by health insurance in Swiss pharmacy channel 2024 (by packs) Substitution rate Pharmacies Galenica Group3 Patent protected products 5.2 million, -1.2% 79.2% Originals/Reference products1 15%
Slide 34: Accelerating generic substitution in 2024
Swiss pharmacy market by drug category Accelerating generic substitution in 2024 Swiss Pharmacy Channel Swiss Pharmacy Channel (Split by value) (Split by volume) 19.6% 19.0% 19.4% 20.3% 46.7% 46.4% 45.9% 45.7% 41.9% 43.8% 45.9% 46.0% 6.1% 6.2% 6.0% 5.9% 18.7% 18.2% 15.4% 19.5% 20.9% 18.9% 16.2% 12.6
Slide 35: Consumer healthcare market FY 2024
Consumer healthcare market FY 2024 Total market 3.0% CHF 2,803.2 million +1.1% 11.9% OTC +2.2% Personal care -1.5% 19.9% Patient care Non-medication +0.3% segment 65.2% -0.8% Nutrition -0.8% Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, streetprices © IQVIA – Consumer Healt
Slide 36: Swiss healthcare market: regulatory environment
Swiss healthcare market: regulatory environment Topic/Initiative Current status Reduction in drug prices − Standard process, FOPH verifies drug prices in a three-year cycle − New concept of distribution margin decided by Federal Council on 8 Dec 2023 Distribution margin − Implementation of a new mod
Slide 37: Constant pressure on drug prices
Swiss healthcare market: regulatory environment Constant pressure on drug prices Annual savings per channel due to price cuts of SL products at public and ex-factory price in million CHF Pharmacies Physicians Hospitals 180 160 31 140 30 120 47 100 ? 12 41 80 34 11 24 11 ? 32 21 60 20 23 9 28 19 40 2
Slide 38: Composition of drug prices
Swiss healthcare market: regulatory environment Composition of drug prices Fixed margin elements help to offset price reductions ~8%1 Per prescription / line Reimbursed → Composition of the price of a ~29% ~ 24% Retail and prescription/ reimbursable drug: ~ 5% Wholesale c.3/4 of the retail margin se
Slide 39: New concept of distribution margin
Swiss healthcare market: regulatory environment New concept of distribution margin (valid since 1 July 2024) FOPH defines price and margin – Margin covers wholesale and retail 70 Current model (until 30 Jun 2024) New model (since 1 Jul 2024) Current model New model 60 Ex factory + price- + surcharge
Slide 40: Business performance
Business performance Our success story
Slide 41: Performance overview Galenica Group
Performance overview Galenica Group History of resilient growth and margin improvement 2014 – 2022 including Mediservice 2023-2024 w/o Mediservice (incl. discontinued operations) (continuing operations) CAGRs CAGRs Retail market sales1 4.2% Retail market sales1 4.3% Galenica net sales 4.2% Galenica
Slide 42: Strong performance development in both segments
Performance overview Galenica Group Strong performance development in both segments Products & Care Logistics & IT 5.4% 4.1% 3.9% 2,030 3,241 1,908 3,077 2,831 2,933 Net sales (CHFm) 1,683 1,6364 1,700 4 1,525 1,621 2,625 1,393 1,437 1,479 2,329 2,362 2,372 2,441 1,335 2,171 2,245 2014 2015 2016 201
Slide 43: Sales growth supported by both segments
Galenica Group Sales growth supported by both segments Net sales (in million CHF) +4.7% 3’921 +5.3% 3’746 3’241 3’077 +3.9% 2023 1’700 1’636 2024 Galenica Group Products & Care Logistics & IT March 2025 Investor Presentation Galenica Group 43
Slide 44: Sales growth supported by both segments
Galenica Group Sales growth supported by both segments Net sales (in million CHF) 2023 2024 change Local Pharmacies 1’306.9 1’365.1 +4.4% Pharmacies at Home 78.9 77.3 -2.1% Retail (B2C) 1’385.6 1’442.0 +4.1% Products & Brands 177.1 183.4 +3.5% Services for Professionals 78.9 84.8 +7.5% Professionals
Slide 45: Retail B2C: Strong sales growth with prescription medicines
Retail B2C Strong sales growth with prescription medicines Net sales (in million CHF) Pharmacies at Home +4.1% Portfolio of local pharmacies Local Pharmacies 1,386 1,442 expanded by 10 locations: 77 -2.1% expansion impact1 of +1.7% 79 +2.4% +5.7% 706 695 747 679 40 38 39 1,365 +4.4% Strong growth of
Slide 46: Products & Brands: Sales growth dampened by mild flu season
Products & Brands Sales growth in H2 dampened by mild flu season Net sales (in million CHF) +3.5% International 177 183 International: Swiss market 41 +16.2% − Organic growth of +15.1% 36 +7.8% -0.9% 90 97 Swiss market: 87 86 − Organic growth of -0.2%1 19 17 24 17 141 142 +0.3% − Growth of CH market
Slide 47: Services for professionals: Strong sales growth in homecare
Services for professionals Strong sales growth in homecare business Net sales (in million CHF) +7.5% 85 79 +7.3% +7.7% Consistent, strong growth with 40 41 43 services for homecare 39 organizations and nursing homes H1 2023 H2 2023 2023 H1 2024 H2 2024 2024 March 2025 Investor Presentation Galenica
Slide 48: Wholesale: Growth supported by market share gains
Wholesale Growth supported by further market share gains Net sales (in million CHF) Physicians +5.2% Pharmacies 3,105 2,953 Others 834 900 +7.8% +2.7% +7.6% Market share gains both in 1,495 1,496 1,609 physicians and pharmacies 1,457 segments 409 425 435 464 1,949 2,028 +4.0% 956 993 972 1’055 92 78
Slide 49: Logistics & IT Services: Sales growth driven by internal IT
Logistics & IT Services Sales growth driven by internal IT services Net sales (in million CHF) +9.2% 157 Intercompany sales 144 Third party sales Solid growth with IT +10.3% +8.1% 80 +14.5% services and pre-wholesale 70 distribution 74 78 80 70 34 36 39 41 74 77 +4.2% 37 38 39 39 H1 2023 H2 2023 202
Slide 50: Strong EBIT growth on a like-for-like basis
Strong EBIT growth on a like-for-like basis EBIT adjusted1 (in million CHF) ROS (in %) 211.0 +4.9% 191.3 201.1 +12.8 56.8 +3.0% 42.3 55.1 1.8% 1.4% 1.8% -3.0 Logistics & IT Products & Care 152.3 149.3 157.3 +5.3% 9.3% 9.1% 9.2% 2023 one-off 2 2023 w/o 2024 items one-off 1 Excluding effects of IAS 19
Slide 51: Adjusted consolidated statement of income
Adjusted consolidated statement of income1 in million CHF 2023 2024 in % Commentary Net sales 3’746 3’921 +4.7% Other income 17 16 -4.8% Cost of goods -2’714 -2’843 +4.7% Cost of goods: Stable gross margin despite strong growth in Wholesale business Personnel costs -556 -583 +4.8% Personnel expenses
Slide 52: Strong balance sheet
Strong balance sheet 1,573 in million CHF 1,482 Equity adjusted1 Net debt adjusted1 424 362 2023 2024 Debt coverage 1.5x 1.6x adjusted2 1 Detail of the adjustments in the Annual Report 2024, see chapter “Alternative performance measures” of the Annual Report 2024 2 Net debt adjusted / EBITDA adjuste
Slide 53: Condensed balance sheet
Condensed balance sheet in million CHF Dec 2023 Dec 2024 Change Commentary Cash and cash equivalents 116 130 +14 Trade and other receivables 518 500 -18 Inventories 357 363 +6 Receivables: Decrease driven by improved receivables management. Other assets 661 705 +43 Other assets: Redcare investment o
Slide 54: Investments
Investments Investment in tangible assets below last year in million CHF 78.8 72.8 32.7 Investments in 36.7 intangible assets Investments in tangible assets 46.1 36.0 2023 2024 in % of net sales 2.1% 1.9% March 2025 Investor Presentation Galenica Group 54
Slide 55: Cash Flow Statement
Cash Flow Statement Operating CF was significantly above prior-year level in million CHF 2023 2024 Commentary Cash flow from operating activities before working Operating Cash Flow: 1 201.3 224.7 capital changes adjusted Significant increase driven by improved profitability, and Working capital chan
Slide 56: Historical dividend per share and pay-out ratio
Share information Historical dividend per share and pay-out ratio1 69.9% Dividend guidance: 68.2% 62.8% 64.7% 59.7% − 50% of dividend payout from reserves from capital 2.30 contributions (exempt from WHT) 2.20 2.20 2.10 − Dividend outlook 2025 at least 1.80 same level as 2024 2020 2021 2022 2023 202
Slide 57: Share information: Key figures
Share information Key figures in CHF Dec 2023 Dec 2024 Share price at reporting date 72.75 74.35 Market capitalisation at reporting date in million CHF 3,625.3 3,704.6 Earnings per share 01/01 – 31/12 from continuing operations1 3.31 3.67 Earnings per share adjusted 01/01 – 31/12 from continuing ope
Slide 58: Governance
1@) 3 Cc a 1e) 0) © | ee i oD =eoameaeP : > i: m9 | \e] " O
Slide 59: Shareholder structure
Shareholder structure Proportion of shareholders by country Major shareholders (31 Dec 2024) (31 Dec 2024) − Shareholders over 3%: in % 0.3% Shareholders Number of shares Shares in % UBS Fund Management (Switzerland) AG, 5,487,581 11.0 Switzerland Switzerland Alecta Pensionsförsäkring, Sweden 2,000,
Slide 60: Overview of our governance structure and instruments
Overview of our governance structure and instruments General Meeting External advisory and inspection bodies / auditors Board of Directors Audit and Remuneration Governance, Nomination and Risk Committee (ARC) Committee (RC) Sustainability Committee (GNSC) Corporate Executive Committee Extended EC P
Slide 61: Board of Directors
Board of Directors1 Dr. Markus − Elected since 2019 Judith Meier − Elected since 2022 R. Neuhaus − Master of law and doctorate in law from the − Executive Master of Health Service Chairman University of Zurich Administration − Vice-Chairman of the Board of Directors of − Member of the Board of Direc
Slide 62: Board of Directors: Committees and competencies
Board of Directors1 Committees and competencies ARC (Audit and Risk Committee) Members: Jörg Zulauf Budget / medium-term planning (Chairman), Bertrand Jungo, Judith Meier Risk management Compliance / internal audits Acquisitions / investments Non-Financial Reporting RC (Remuneration Committee) Membe
Slide 63: Board of Directors: Competencies and diversity
Board of Directors1 Competencies and diversity Competencies Neuhaus Bruderer Jungo Meier Peters Zulauf Markus Pascale Bertrand Judith Solange Jörg Industry x x x x Experience Digitalisation (x) (x) (x) x Regulations/ x x x x Politics Leadership/ x x x x Big Corp. Finance/ An (x) in brackets refers t
Slide 64: Board of Directors: Competencies and diversity
Board of Directors1 Competencies and diversity Age of BoD members Gender of BoD members (December 2024) (December 2024) 46 - 50: 17% 51 - 55: 33% 56 - 60: male 17% 61 - 65: 50% 50% female 66 - 70: 17% 17% 1 The Board of Directors as of 31.12.2024 March 2025 Investor Presentation Galenica Group 64
Slide 65: Our organisation
Our organisation March 2025 Investor Presentation Galenica Group 65
Slide 66: Our leadership team
Our leadership team Executive Committee Extended Executive Committee Marc Werner Julian Fiessinger Lukas Ackermann Arianne Hasler Andreas Koch Iris Müller Jürg Pauli CEO CFO Chief IT & Digital Chief People & Culture Chief Wholesale & Chief Corporate Chief Sustainability, Public Business Logistics Co
Slide 67: Remuneration
Remuneration Responsibility for the remuneration process Remuneration Level of authority CEO Board of Directors Annual General Meeting Committee consultative vote on the Remuneration policy proposes approves Remuneration report Performance objectives for short-term proposes approves bonus and long-t
Slide 68: Remuneration
Remuneration Remuneration components STI LTI − The remuneration components of the Corporate Executive Committee (EC) 25% ESG 50% consists of a fixed compensation, benefits and a variable compensation. average − The variable remuneration consists of a short-term incentive (STI) and a long- GEP term i
Slide 69: Sustainability
* alenica ‘Sustainability:
Slide 70: Sustainability at Galenica: Overview
Sustainability at Galenica Overview Sustainability Guidelines Company value Employees Resource efficiency We increase the value of the We oblige our employees to act We use resources sparingly company in the long term by responsibly and ensure they have and efficiently and reduce having a sustainabl
Slide 71: Matrix of the main topics
Sustainability at Galenica Matrix of the main topics March 2025 Investor Presentation Galenica Group 71
Slide 72: Our sustainability goals
Sustainability at Galenica Our sustainability goals Corporate governance Patients Ethical and legal business activities Increase patient and health safety Protect patient data and IT systems Ensure the availability of medicinal products Employees Environment Promote employee motivation and developme
Slide 73: Our sustainability goals
Sustainability at Galenica Our sustainability goals Target Measurement Goal Status year parameter 2022 2023 2024 We train our employees in compliance several times a year, tailored to the Every year Number of measures N/A 4 7 respective target group. Several times per year, we carry out measures to
Slide 74: Our sustainability goals
Sustainability at Galenica Our sustainability goals Target Goal Status year Measurement parameter 2022 2023 2024 We will increase the use of Clinical Number of CDS.CE checks Decision Support Checks (CDS.CE) to 500 2030 110 million 278 million 369 million (Clinical Decision Support) million by 2025 a
Slide 75: Our sustainability goals
Sustainability at Galenica Our sustainability goals Target Goal Status year Measurement parameter 2022 2023 2024 Employee survey "Opinio": We will increase the participation rate by 1 Motivation rate 74 / 100 76 / 100 76 / 100 Every percentage point per year and keep the = Recommendation rate n/a 76
Slide 76: Our sustainability goals
Sustainability at Galenica Our sustainability goals Goal Status Target year Measurement parameter 2022 2023 2024 From 2025, we will be sourcing 100% of our electricity from % electricity from renewable 2025 74% 75% 100% renewable sources at all our sources per location locations. We will reduce the
Slide 77: ESG Ratings
ESG Ratings Rating-Agentur Actual Rating Percentile Comment ESG Risk Top 2% (Global Universe) − Ranking number 9 among 634 Healthcare companies (Rating of 11.3) NEGL LOW MED HIGH SEVERE − Very good scores in Business ethics, Data privacy and security, and Carbon emissions in own (Aug 2024) 0% 100% o
Slide 78: Outlook
Outlook
Slide 79: Outlook: Products & Care priorities 2025
Outlook Products & care The rNPS (Net The collaboration Promoter Score) is The online between Bichsel, The importance of to be introduced Continuous presence of Mediservice, the pharmacy as across the board in optimisation and Galenica Medifilm, Lifestage the first point of pharmacies from reinforce
Slide 80: Outlook: Logistics & IT
Outlook Logistics & IT Implementation of Galexis: measures to achieve the The Documedis® Following the successful sustainability goals is a software solution from − Lausanne-Ecublens: pilot projects, the “e- top priority HCI Solutions is to be ERP replacement at prescription” is to be implemented as
Slide 81: Financial guidance 2025
Financial guidance 2025 Galenica expects slightly stronger EBIT growth in 2025. − Galenica Group net sales +3% to +5% − EBIT adjusted1 +4% to +6% − Dividend for 2025 at least at prior-year level 1 Excluding effects of IAS 19 and IFRS 16, see chapter “Alternative performance measures” of the Annual R
Slide 82: Market development expectations
Market development expectations1 • Based on the demographic trends and innovation with many new, high-priced medications, Galenica expects continued strong growth of +/- 5% in the Swiss pharmaceutical market2 in the next years. • The strongest growth is expected in the hospital channel. For pharmaci
Slide 83: Mid-term Guidance
Mid-term Guidance • Galenica expects net sales to grow by 3% to 5% in the next years. • Until 2026, Galenica expects a stable development of its return on sales (ROS)1 due to • an intense final phase of the ERP project in the Logistics & IT segment with a planned finalisation in 2026, • continuous i
Slide 84: Reasons to invest in Galenica
Reasons to invest in Galenica Unique combination of defensive resilience and significant growth Defensive resilience History of growth Strategic focus • Stable and attractive Swiss • Significant operational • Proven strategy to leverage healthcare market with advantages from integrated, market leade
Slide 85: Galenica Group – Contact information
Galenica Group – Contact information Investor Relations Julian Fiessinger Tel: +41 58 852 85 31 CFO investors@galenica.com Florian Urech Tel: +41 58 852 83 42 Head of Investor Relations investors@galenica.com and Corporate Finance March 2025 Investor Presentation Galenica Group 85
Slide 86: Disclaimer
Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a n